19 results
8-K
EX-4.1
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.3
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.2
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
NKGN
NKGen Biotech Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-4.1
i8dfdpcnjom k8ko7
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.2
ig8qu3sadkd3u x8xh
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.2
axdwqin4q4egwf1
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-4.1
ypjwt5p ah
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-4.1
hy0tgp6jj
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-4.2
fx51x lh82z
5 Oct 23
Index to Financial Statements
5:12pm
425
EX-4.1
u1wx2rdhgd2si6vsl
19 Sep 23
Business combination disclosure
3:52pm
8-K
EX-4.1
7xrsiw0 z8nsgj0ne
19 Sep 23
Entry into a Material Definitive Agreement
3:51pm
10-K
EX-4.5
naw633jt
30 Mar 22
Annual report
9:27pm
8-K
EX-4.1
5s3qmmr9y416zyh
25 May 21
Graf Acquisition Corp. IV Announces Pricing of $150 Million Initial Public Offering
5:10pm
- Prev
- 1
- Next